AJMC Staff

Featuring stories about single-payer healthcare, studies on alcohol, and superbugs.

Pembrolizumab has been approved as first-line treatment for patients with unresectable or metastatic melanoma.

The 32-year-old was arrested on charges related to his prior work as a hedge fund manager.

What we're reading, December 18, 2015: HHS report finds generic drug prices rising faster than inflation; UnitedHealthcare's real-time drug approval tool; and government overcharged by private Medicare Advantage plans.

What we're reading, December 17, 2015: Congress is expected to pass a spending plan that includes 3 changes to the Affordable Care Act; a new analysis estimates 2016 premiums for marketplace plans will increase 11%; and one-third of Americans die from cardiovascular disease.

NICE rejects promising oncology agents once again, citing high drug cost.

What we're reading, December 16, 2015: a new study casts doubt on what experts thought they knew about healthcare costs; unprecedented interest in health insurance coverage has prompted the government to extend the deadline for full-year 2016 coverage; and a law to create multi-state health plans won't reach it's 2017 goal.

What we're reading, December 15, 2015: call centers overwhelmed by last-minute rush for health insurance enrollment; AstraZeneca exploring deal with Acerta Pharma; and despite near universal health insurance coverage in Massachusetts, patients have access issues.

There is, currently, an unmet need in bladder cancer, a disease expected to be responsible for 16,000 deaths in 2015.

What we're reading, December 14, 2015: public health initiatives are underfunded despite being a big return on investment; the FDA repeatedly approved the cancer drug Afinitor without proof it extended life; and a nurse may have exposed patients in a maternity wing to tuberculosis.

What we're reading, December 11, 2015: CMS penalized hospitals for patient safety deficiences; MedPAC approved reducing Medicare Advantage plan reimbursement; and Kentuckians favor keeping Medicaid expansion.

On Tuesday, December 15, from 11 am to noon EST, The American Journal of Managed Care will host a tweetchat with Leah Binder, MA, MGA, president and CEO of The Leapfrog Group, about hospital quality ratings, patient safety, and healthcare outcomes.

What we're reading, December 10, 2015: the Affordable Care Act has signed up 1 million new enrollees; Medicare patients spend more on oral cancer drugs than food each year; and the CDC found life expectancy remains at 79 years for the third year in a row.

The DigniCap Cooling System reduces the frequency and severity of alopecia during chemotherapy in breast cancer patients.

What we're reading, December 9, 2015: the federal government recovered $200 million from state's whose health insurance exchanges faltered; drug cocktails are responsible for majority of drug overdose deaths in Massachusetts; and healthcare organizations are not confident in their ability to share patient data while protecting patient privacy.

What we're reading, December 8, 2015: Cigna remains committed to participation in Obamacare exchanges; Puerto Rico demands the US fix healthcare funding disparities; and fewer Americans struggle to pay medical bills.

Low-carb diets high in animal based foods were more associated with a risk of type 2 diabetes than plant-based diets.

What we're reading, December 7, 2015: Mylan is subpoenaed over pricing of generic doxycycline antibiotic products; Congressional hearing this week on drug pricing controversy; new superbug on the rise; and Obamacare penalty for being uninsured may not be enough to get people to sign up.

What we're reading, December 4, 2015: restaurant group sues New York City over salt warnings rule; Turing CEO remains unapologetic over Daraprim price hike; and women face a higher risk of needing costly, long-term care.

What we're reading, December 3, 2015: health spending in the US topped $3 trillion in 2014; experts debate the true impact of proposed health insurer mega-mergers; and a survey finds ICD-10 transition has been mostly without trouble.

Critics of the Global Energy Balance Network had compared its work to the tactics of big tobacco, which decades ago had sponsored studies to dissuade Americans that cigarettes were dangerous.

What we're reading, December 2, 2015: Gilead priced Sovaldi knowing the high cost would be a challenge for patients and payers; Senate Republicans will vote Thursday on Obamacare repeal and expect to get the needed votes; and a report calls for a better focus on women's health.

What we're reading, December 1, 2015: $1 alternative to Daraprim being made available; over-the-counter medications are convenient and affordable but have their own dangers; and an analysis looks at the reasons why prescription drugs are so much more expensive in the US.

What we're reading, November 30, 2015: the Spanish language HealthCare.gov is lagging in sign-ups; the overall federal insurance exchange has fewer preferred provider organizations; and many Americans don't understand why they need the flu vaccine.

The link between low testosterone and decreased insulin sensitivity had been shown in previous research.

Here are the top 5 papers published by The American Journal of Managed Care and its sister publications about hepatitis C, treatment, and costs of care.

What we're reading, November 25, 2015: UnitedHealthcare's decision on healthcare exchange participation, Democratic Presidential candidate's health plan, and conflict of interest between soda company and anti-obesity research group.

What we're reading, November 25, 2015: hospitals can save money in the long run by preventing hospital-acquired infections with private rooms; Arizona's co-op plans to close December 31; and study finds testing prison inmates for hepatitis C is extremely cost-effective.

What we're reading, November 26, 2015: CMS blog on step-wise transition to value-based care, payer-drug industry alliance on drug pricing, and a new model to override the proposed ACA tax credits.

What we're reading, November 24, 2015: expensive hepatitis C drugs are more cost effective when used earlier; clinicians aren't prescribing generics enough; and half of health 45-year-olds will develop prediabetes.